Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 450-457

  Knappe, Sabine ^b   Gorczyca, Monika E ^a   Jilma, Bernd ^a   Derhaschnig, Ulla ^a   Hartmann, Rudolf ^b   Palige, Michael ^b   Scheiflinger, Fritz ^b   Dockal, Michael ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Calibrated automated thrombin generation assay (CAT); Coagulation factor FVIII; Haemophilia; Rotational thromboelastometry (ROTEM); TFPI; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD CLOT; BLOOD CLOTTING; BLOOD CLOTTING TIME; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION COEFFICIENT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLE SIZE; STATISTICAL ANALYSIS; THROMBOELASTOGRAPHY;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOPHILIA A; HEMOSTASIS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; THROMBELASTOGRAPHY; THROMBIN; TIME FACTORS;

EID: 84874778806     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0529     Document Type: Article

References (35)

1. Tagariello G, Iorio A, Santagostino E, et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-784.
2. Santagostino E, Mancuso ME, Tripodi A, et al. Severe haemophilia with mild bleeding phenotype: molecular characterisation and global coagulation profile. J Thromb Haemost 2010; 8: 737-743.
3. van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe haemophilia. J Thromb Haemost 2007; 5 (Suppl 1): 151-156.
4. Broze GJ, Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
5. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28: 233-242.
6. Kasthuri RS, Glover SL, Boles J, et al. Tissue factor and tissue factor pathway inhibitor as key regulators of global haemostasis: measurement of their levels in coagulation assays. Semin Thromb Haemost 2010; 36: 764-771.
7. Brodin E, Appelbom H, Osterud B, et al. Regulation of thrombin generation by TFPI in plasma without and with heparin. Translational Res 2009; 153: 124-131.
8. Liu T, Scallan CD, Broze GJ, Jr., et al. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
9. Nordfang O, Valentin S, Beck TC, et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of haemophilia plasma. Thromb Haemost 1991; 66: 464-467.
10. Parunov LA, Fadeeva OA, Balandina AN, et al. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011; 9: 1825-1834.
11. Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and haemophiliac plasmas. Thromb Res 1991; 64: 213-222.
12. Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6: 388-394.
13. Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class haemostatic drug candidate, AV513, in dogs with haemophilia A. Blood 2008; 111: 672-679.
14. Waters EK, Genga RM, Schwartz MC, et al. Aptamer ARC19499 mediates a procoagulant haemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-5522.
15. Hilden I, Lauritzen B, Sorensen BB, et al. Haemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit haemophilia model. Blood 2012; 119: 5871-5878.
16. Gorczyca ME, Nair SC, Jilma B, et al. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of haemophilic blood and plasma. J Thromb Haemost 2012; 10: 1581-1590.
17. Maurissen LF, Castoldi E, Simioni P, et al. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8: 750-758.
18. Jilma-Stohlawetz P, Kursten FW, Walasek C, et al. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized double-blind, clinical trial in healthy volunteers. Transfusion 2011; 51: 1228-1240.
19. Leitner JM, Jilma B, Spiel AO, et al. Massive pulmonary embolism leading to cardiac arrest is associated with consumptive coagulopathy presenting as disseminated intravascular coagulation. J Thromb Haemost 2010; 8: 1477-1482.
20. Jilma B, Paulinska P, Jilma-Stohlawetz P, et al. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104: 563-570.
21. Jilma-Stohlawetz P, Knobl P, Gilbert JC, et al. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012; 108: 284-290.
22. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33: 4-15.
23. Machlus KR, Colby EA, Wu JR, et al. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost 2009; 102: 936-944.
24. Spiel AO, Mayr FB, Firbas C, et al. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006; 4: 411-416.
25. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239.
26. Antovic JP, Mikovic D, Elezovic I, et al. Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A. Thromb Haemost 2012; 108: 21-31.
27. Livnat T, Martinowitz U, Zivelin A, et al. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 2011; 105: 688-695.
28. Hvas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J Thromb Haemost 2007; 5: 2408-2414.
29. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14 (Suppl 3): 83-92.
30. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitztype inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520.
31. van't Veer C, Mann KG. Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II. J Biol Chem 1997; 272: 4367-4377.
32. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
33. Valentino LA. Blood-induced joint disease: the pathophysiology of haemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-1902.
34. Nagel K, Walker I, Decker K, et al. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011; 17: 872-874.
35. Tardy-Poncet B, Piot M, Chapelle C, et al. Difference in TFPI levels between haemophilia A and B patients. Haemophilia 2011; 17: 312-313.